BioCryst Pharmaceuticals, Inc. (BCRX) Issues Earnings Results, Hits Estimates
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) released its earnings results on Monday. The biotechnology company reported ($0.18) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.18), Bloomberg Earnings reports. The business had revenue of $8.76 million during the quarter, compared to the consensus estimate of $5.05 million. BioCryst Pharmaceuticals had a negative net margin of 160.97% and a negative return on equity of 276.62%. The firm’s revenue for the quarter was up 12.9% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.16) earnings per share.
BioCryst Pharmaceuticals (NASDAQ BCRX) traded down $0.10 during mid-day trading on Tuesday, reaching $4.75. 623,711 shares of the company’s stock traded hands, compared to its average volume of 1,100,000. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.54 and a current ratio of 1.57. BioCryst Pharmaceuticals has a 52-week low of $3.92 and a 52-week high of $9.25.
COPYRIGHT VIOLATION WARNING: This article was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/11/07/biocryst-pharmaceuticals-inc-bcrx-issues-earnings-results-hits-estimates.html.
A number of analysts have recently issued reports on the stock. Royal Bank Of Canada assumed coverage on shares of BioCryst Pharmaceuticals in a research note on Thursday, September 14th. They set a “sector perform” rating and a $6.00 target price for the company. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a research note on Wednesday, September 6th. J P Morgan Chase & Co raised their target price on shares of BioCryst Pharmaceuticals from $4.93 to $9.00 and gave the stock a “neutral” rating in a research note on Wednesday, September 6th. Jefferies Group LLC upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and raised their target price for the stock from $5.00 to $7.00 in a research note on Wednesday, September 6th. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $15.00 target price (up previously from $13.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday, September 5th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $8.78.
In other BioCryst Pharmaceuticals news, Director Fred E. Cohen sold 54,250 shares of the firm’s stock in a transaction dated Monday, September 18th. The shares were sold at an average price of $5.42, for a total value of $294,035.00. Following the transaction, the director now directly owns 173,660 shares of the company’s stock, valued at approximately $941,237.20. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 5.60% of the stock is owned by company insiders.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
Receive News & Stock Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.